Characterizing the relationships between patient‐reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib

BACKGROUND: The phase 2a ALLEGRO trial (NCT02974868) investigated the safety and efficacy of ritlecitinib (PF‐06651600) and brepocitinib (PF‐06700841) in adults with alopecia areata. No randomized controlled trial for alopecia areata has evaluated correlations between clinician‐assessed hair loss an...

Descripción completa

Detalles Bibliográficos
Autores principales: Winnette, R., Banerjee, A., Sikirica, V., Peeva, E., Wyrwich, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Hair
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303953/
https://www.ncbi.nlm.nih.gov/pubmed/35000236
http://dx.doi.org/10.1111/jdv.17909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303953/
https://www.ncbi.nlm.nih.gov/pubmed/35000236
http://dx.doi.org/10.1111/jdv.17909

Ejemplares similares